Source: Breathe 2014; 10:110-120
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Cazzola Mario, Page Clive. Long-acting bronchodilators in COPD: where are we now and where are we going?. Breathe 2014; 10:110-120

Member's Comments

No comment yet.

Related content which might interest you: What to use INSTEAD of inhaled corticosteroids in COPD? Source: Eur Respir J 2014; 44: 1391-1393 Year: 2014 Inhaled beta2-agonists in asthma management: an evolving story Source: Breathe 2016; 12: 375-377 Year: 2016 Is it time to move away from short-acting beta-agonists in asthma management? Source: Eur Respir J, 53 (4) 1802223; 10.1183/13993003.02223-2018 Year: 2019 Is there a problem with inhaled corticosteroid use in COPD? Source: Virtual Congress 2020 – Airway diseases Year: 2020 The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014 Optimising bronchodilator therapy in COPD: Who, why and when? Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care Year: 2019 Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Inhaled corticosteroids in COPD: the case against Source: Eur Respir J 2009; 34: 13-16 Year: 2009 Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence? Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020 Knowing when to stop: inhaled corticosteroids and COPD Source: Eur Respir J 2015; 46: 1236-1238 Year: 2015 Are bronchodilator drugs really useful in COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001 Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Inhaled corticosteroids in COPD: a case in favour Source: Eur Respir J 2009; 34: 10-12 Year: 2009 Inhaled beta2-agonists and death for asthma: can we overcome this risk? Source: Annual Congress 2007 - Effect of long acting beta-agonists on severe asthma exacerbations and asthma-related deaths Year: 2007 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients? Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004 Inhaled corticosteroids in treatment of patients with intermittent bronchial asthma: yes or no? Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005 Anti-inflammatory therapy COPD: fenspiride and(or) theophylline versus inhaled corticosteroids? Source: Annual Congress 2007 - Treatment of COPD Year: 2007 Targeting neuropetides: from antiemetics to bronchodilators? Source: Annual Congress 2012 - ERS Romain Pauwels Research Award Ceremony (supported by GlaxoSmithKline) followed by the Hot Topic "The nerves are back!" Year: 2012